| pubmed-article:12966464 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0015733 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0002191 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0003211 | lld:lifeskim |
| pubmed-article:12966464 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:12966464 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12966464 | pubmed:dateCreated | 2003-9-10 | lld:pubmed |
| pubmed-article:12966464 | pubmed:abstractText | Fecal alpha(1)-proteinase inhibitor (alpha(1)-PI) clearance is a reliable, noninvasive marker for protein-losing enteropathy (PLE) in human beings. An assay for measurement of this protein in the dog has been developed and validated and may be useful for the investigation of gastrointestinal disease in this species. Nonsteroidal anti-inflammatory drugs (NSAIDs) frequently are administered to dogs and may have adverse effects on the gastrointestinal tract, including gastroduodenal ulceration and altered mucosal permeability. The value of fecal alpha(1)-PI measurement in detecting unrelated gastrointestinal disease may be limited in dogs on NSAID therapy, but alpha(1)-PI may be a useful marker for NSAID-induced gastrointestinal damage. | lld:pubmed |
| pubmed-article:12966464 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12966464 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12966464 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12966464 | pubmed:issn | 0275-6382 | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:HallE JEJ | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:WilliamsD ADA | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:MurphyK FKF | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:SteinerJ MJM | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:GermanA JAJ | lld:pubmed |
| pubmed-article:12966464 | pubmed:author | pubmed-author:RuauxC GCG | lld:pubmed |
| pubmed-article:12966464 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12966464 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:12966464 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12966464 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12966464 | pubmed:pagination | 136-9 | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:meshHeading | pubmed-meshheading:12966464... | lld:pubmed |
| pubmed-article:12966464 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12966464 | pubmed:articleTitle | Fecal alpha1-proteinase inhibitor concentration in dogs receiving long-term nonsteroidal anti-inflammatory drug therapy. | lld:pubmed |
| pubmed-article:12966464 | pubmed:affiliation | Department of Clinical Veterinary Science, University of Bristol, Bristol, UK. kate.murphy@bristol.ac.uk | lld:pubmed |
| pubmed-article:12966464 | pubmed:publicationType | Journal Article | lld:pubmed |
